EA034135B9 - Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов - Google Patents
Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторовInfo
- Publication number
- EA034135B9 EA034135B9 EA201591598A EA201591598A EA034135B9 EA 034135 B9 EA034135 B9 EA 034135B9 EA 201591598 A EA201591598 A EA 201591598A EA 201591598 A EA201591598 A EA 201591598A EA 034135 B9 EA034135 B9 EA 034135B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyreceptor
- agonists
- pharmaceutical compositions
- nucleoside derivatives
- compositions based
- Prior art date
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title abstract 2
- 229940045145 uridine Drugs 0.000 title abstract 2
- -1 uridine nucleoside derivatives Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780219P | 2013-03-13 | 2013-03-13 | |
| US201361883604P | 2013-09-27 | 2013-09-27 | |
| PCT/US2014/026865 WO2014160502A1 (en) | 2013-03-13 | 2014-03-13 | Uridine nucleoside derivatives, compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201591598A1 EA201591598A1 (ru) | 2016-03-31 |
| EA034135B1 EA034135B1 (ru) | 2020-01-09 |
| EA034135B9 true EA034135B9 (ru) | 2020-04-10 |
Family
ID=51625444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591598A EA034135B9 (ru) | 2013-03-13 | 2014-03-13 | Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10544183B2 (enExample) |
| EP (2) | EP2968385B1 (enExample) |
| JP (1) | JP6591957B2 (enExample) |
| KR (1) | KR102304242B1 (enExample) |
| CN (1) | CN105407898B (enExample) |
| AU (1) | AU2014243707B2 (enExample) |
| CA (1) | CA2904180C (enExample) |
| DK (1) | DK2968385T3 (enExample) |
| EA (1) | EA034135B9 (enExample) |
| ES (1) | ES2684368T3 (enExample) |
| HU (1) | HUE039871T2 (enExample) |
| IL (1) | IL241172B (enExample) |
| PL (1) | PL2968385T3 (enExample) |
| PT (1) | PT2968385T (enExample) |
| SI (1) | SI2968385T1 (enExample) |
| TW (1) | TWI640533B (enExample) |
| WO (1) | WO2014160502A1 (enExample) |
| ZA (1) | ZA201507045B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014CN03043A (enExample) * | 2011-09-30 | 2015-07-03 | Univ Tufts | |
| JP6523958B2 (ja) | 2012-09-28 | 2019-06-05 | タフツ・ユニバーシティ | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
| PT2968385T (pt) | 2013-03-13 | 2018-10-09 | Univ Tufts | Derivados nucleósidos de uridina, composições e métodos de uso |
| AR095442A1 (es) | 2013-03-13 | 2015-10-14 | Univ Tufts | Derivados de nucleósido de uridina, composiciones y métodos de uso |
| ES2989621T3 (es) | 2016-04-21 | 2024-11-27 | Astrocyte Pharmaceuticals Inc | Compuestos y métodos para el tratamiento de afecciones neurológicas y cardiovasculares |
| JP7311855B2 (ja) | 2018-02-09 | 2023-07-20 | アストロサイト ファーマシューティカルズ， インコーポレイテッド | 嗜癖および関連する障害を処置するための化合物および方法 |
| AU2019346585B2 (en) | 2018-09-26 | 2025-02-27 | Astrocyte Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| US12285182B2 (en) | 2018-10-10 | 2025-04-29 | Innova Vascular, Inc. | Devices and methods for removing an embolus |
| WO2021026337A1 (en) * | 2019-08-07 | 2021-02-11 | Icahn School Of Medicine At Mount Sinai | Method of treating keloids |
| CN116437930A (zh) * | 2020-10-30 | 2023-07-14 | 上海岸阔医药科技有限公司 | 尿苷衍生物在制备药物中的应用 |
| WO2022266027A1 (en) * | 2021-06-15 | 2022-12-22 | Steven Baranowitz | Prevention and treatment of post-infection neurological disorders and clotting/thrombotic disorders |
| CN116712448A (zh) * | 2022-11-11 | 2023-09-08 | 上海市皮肤病医院 | 一种治疗银屑病的药物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013049686A1 (en) * | 2011-09-30 | 2013-04-04 | Tufts University | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0621073B2 (ja) | 1986-03-06 | 1994-03-23 | 日水製薬株式会社 | 中枢抑制剤 |
| JP3032053B2 (ja) | 1991-09-06 | 2000-04-10 | 日水製薬株式会社 | ウリジン誘導体及びこれを含有する医薬 |
| US5962459A (en) | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| ATE288273T1 (de) * | 1997-08-29 | 2005-02-15 | Univ North Carolina | Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen |
| US6989376B2 (en) | 1998-07-31 | 2006-01-24 | Massachusetts Institute Of Technology | Methods for increasing blood cytidine and/or uridine levels and treating cytidine-dependent human diseases |
| US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| US20050203053A1 (en) | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| US20060069061A1 (en) | 1998-07-31 | 2006-03-30 | Dick Wurtman | Compositions containing uridine and choline, and methods utilizing same |
| US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US20050074819A1 (en) | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
| WO2005122767A1 (en) | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| JP2008513453A (ja) * | 2004-09-15 | 2008-05-01 | マサチューセッツ インスティテュート オブ テクノロジー | ウリジンを含んだ組成物及びその使用方法 |
| CN101237772A (zh) * | 2005-06-29 | 2008-08-06 | 印斯拜尔药品股份有限公司 | 用于治疗肺病的p2y6受体激动剂 |
| US7851456B2 (en) * | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| CN101765369A (zh) | 2007-03-19 | 2010-06-30 | 俄勒冈州由俄勒冈州立大学代表州高等教育委员会行使 | 曼尼希碱n-氧化物药物 |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| JP2012513953A (ja) | 2008-09-23 | 2012-06-21 | アルニラム ファーマスーティカルズ インコーポレイテッド | 付加環化を用いたモノマーおよびオリゴヌクレオチドの化学修飾 |
| IT1398378B1 (it) | 2010-02-22 | 2013-02-22 | Omikron Italia S R L | Citicolina per il trattamento del glaucoma e dell'ipertensione oculare. |
| EP2646449B1 (en) * | 2010-12-01 | 2015-08-19 | Bar-Ilan University | Uridine di- or tri-phosphate derivatives and uses thereof |
| JP6523958B2 (ja) | 2012-09-28 | 2019-06-05 | タフツ・ユニバーシティ | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
| PT2968385T (pt) * | 2013-03-13 | 2018-10-09 | Univ Tufts | Derivados nucleósidos de uridina, composições e métodos de uso |
| AR095442A1 (es) * | 2013-03-13 | 2015-10-14 | Univ Tufts | Derivados de nucleósido de uridina, composiciones y métodos de uso |
-
2014
- 2014-03-13 PT PT14775026T patent/PT2968385T/pt unknown
- 2014-03-13 WO PCT/US2014/026865 patent/WO2014160502A1/en not_active Ceased
- 2014-03-13 HU HUE14775026A patent/HUE039871T2/hu unknown
- 2014-03-13 SI SI201430843T patent/SI2968385T1/sl unknown
- 2014-03-13 PL PL14775026T patent/PL2968385T3/pl unknown
- 2014-03-13 JP JP2016502267A patent/JP6591957B2/ja not_active Expired - Fee Related
- 2014-03-13 EA EA201591598A patent/EA034135B9/ru unknown
- 2014-03-13 DK DK14775026.9T patent/DK2968385T3/en active
- 2014-03-13 AU AU2014243707A patent/AU2014243707B2/en not_active Ceased
- 2014-03-13 EP EP14775026.9A patent/EP2968385B1/en active Active
- 2014-03-13 TW TW103109174A patent/TWI640533B/zh not_active IP Right Cessation
- 2014-03-13 CA CA2904180A patent/CA2904180C/en active Active
- 2014-03-13 KR KR1020157028543A patent/KR102304242B1/ko not_active Expired - Fee Related
- 2014-03-13 ES ES14775026T patent/ES2684368T3/es active Active
- 2014-03-13 US US14/775,426 patent/US10544183B2/en not_active Expired - Fee Related
- 2014-03-13 CN CN201480023822.XA patent/CN105407898B/zh not_active Expired - Fee Related
- 2014-03-13 EP EP18173639.8A patent/EP3449925B1/en active Active
-
2015
- 2015-09-03 IL IL241172A patent/IL241172B/en active IP Right Grant
- 2015-09-22 ZA ZA2015/07045A patent/ZA201507045B/en unknown
-
2020
- 2020-01-27 US US16/773,406 patent/US11124536B2/en not_active Expired - Fee Related
-
2021
- 2021-08-12 US US17/400,515 patent/US20220135611A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013049686A1 (en) * | 2011-09-30 | 2013-04-04 | Tufts University | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
Non-Patent Citations (10)
| Title |
|---|
| BANERJEE, D. et al., "Efficient and Convenient Palladium-Catalyzed Amination of Allylic Alcohols with N-Heterocycles", Angewandte Chemie International Edition (2012), Vol. 51, No. 46, pages 11556-11560, see compound 3r, scheme 3 * |
| CAS RN 106362-71-4 * |
| CAS RN 110104-24-0 * |
| CAS RN 114766-52-8 * |
| CAS RN 129141-73-7 * |
| CAS RN 166190-75-6 * |
| CAS RN 166190-76-7 * |
| CAS RN 50908-28-6 * |
| CAS RN 51172-66-8 * |
| KIMURA, T. et al., "Metabolism of a novel hypnotic, N3-phenacyluridine, and hypnotic and sedative activities of its enantiomer metabolites in mouse", Xenobiotica (2000), Vol. 30, No. 6, pages 643-653, see Abstract section 6; table 2; figure 6 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA034135B9 (ru) | Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| MX2017006302A (es) | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| WO2015108490A3 (en) | Heteroaryl alkyne derivatives and uses thereof | |
| MY199705A (en) | Heterocyclic compounds as immunomodulators | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| PH12015500963A1 (en) | Tricyclic fused thiophene derivatives as jak inhibitors | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MX2016008110A (es) | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. | |
| MX2016002238A (es) | Alcoholes de alquilino y metodos de uso. | |
| MX2015010125A (es) | Derivados de piridazinona-amidas. | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| MX2016002241A (es) | Alcoholes de alquinilo y metodos de uso. | |
| NZ708727A (en) | Conjugate compounds | |
| MX373549B (es) | Derivado de pirazol amida. | |
| MX2020006614A (es) | Derivados de cromenopiridina como inhibidores de fosfatidilinositol fosfato cinasa,. | |
| WO2014151456A3 (en) | Treatment of inflammatory diseases | |
| IN2014CN03043A (enExample) | ||
| TN2015000120A1 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent |